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Article

Echogenic Intracardiac Foci
Associated With Increased Risk for
Fetal Trisomy 21 or Not?
Anthony L. Shanks, MD, Anthony O. Odibo, MD, MSCE,
Diana L. Gray, MD
Objective. The purpose of this study was to evaluate the impact of an echogenic intracardiac focus
(EIF) on the risk for fetal trisomy 21 (T21) in populations with differing prevalence of T21. Methods. A
retrospective cohort study of pregnancies presenting to our prenatal ultrasound units over 16 years
(1990–2006) was conducted. Contingency table analysis of the presence of an EIF and diagnosis of
fetal T21 was performed. The groups analyzed included the following: (1) all fetuses with EIF plus other
sonographic markers, (2) EIF as an isolated sonographic marker, (3) those younger than 35 years with
an isolated finding of EIF, and (4) a group with an isolated finding of EIF excluding those at increased
risk for T21 on serum screening. Results. Echogenic intracardiac foci were found in 2223 of 62,111
pregnancies (3.6%), and T21 was diagnosed in 218 pregnancies (0.4%). The presence of an EIF along
with other markers was associated with a statistically significant risk for T21 (positive likelihood ratio
[LR], 4.4; 95% confidence interval [CI], 3.2–6.0; P < .05). An isolated EIF was not associated with a statistically significant increased risk for T21 in patients younger than 35 years (positive LR, 1.7; 95%, CI
0.7–4.1) and those without abnormal serum screening results for aneuploidy (positive LR, 1.6; 95%
CI, 0.8–3.1). Conclusions. The finding of an isolated EIF on prenatal sonography does not significantly increase the risk for fetal T21 in populations not otherwise at an increased risk for the disorder. An
isolated EIF should be considered an incidental finding in patients younger than 35 years and in those
without abnormal serum aneuploidy screening results. Key words: Down syndrome; echogenic intracardiac focus; fetal trisomy 21; prenatal diagnosis; sonography.
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A

n echogenic intracardiac focus (EIF) is defined
as an echogenic area appearing within the heart
that has sonographic brightness equivalent to
that of bone. It is a finding commonly detected
during routine anatomic surveys. Echogenic intracardiac
foci represent microcalcification and fibrosis of the papillary muscle or chordae but are not by themselves associated with myocardial dysfunction or cardiac structural
anomalies.1,2
Echogenic intracardiac foci were initially considered
normal variants. However, pathologic literature in the
early 1990s began to suggest a potential association with
trisomy 21 (T21). A case report of 3 fetuses with papillary
mineralization noted that 1 of the 3 subsequently was
discovered to have T21.3 Another study noted that 16% of
fetuses with T21 had microcalcification of the papillary
muscles.4 This was in contrast to only 2% of fetuses with
normal chromosome constitutions with this finding. Many
studies linking the presence of an EIF to an increased risk
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for T21 soon followed. A meta-analysis in 2003
reported that 15% to 30% of fetuses with T21 had
an EIF, whereas this finding was present in only
4% to 7% of unaffected fetuses.5 The conclusion
was that the presence of an EIF increased the risk
of Down syndrome.
More recent studies have attempted to clarify
the impact of EIF detection during sonographic
evaluation of the fetus. Recent evidence has suggested that the finding of an isolated EIF does not
confer an increased risk for T21.6–8 Additionally,
the initial studies used patients referred for invasive genetic testing, which represented a high-risk
patient population. It is unclear whether the
results of these studies could be applied to lowrisk patients (eg, patients <35 years and patients
with normal serum aneuploidy screening results).
The current body of literature describes trends
but does not provide tangible adjusted risk estimates to aid in counseling. Most of these studies
were limited by the low prevalence of T21 in lowrisk groups. The objective of the study was to
evaluate the impact of an EIF on the risk of fetal
T21 in populations with differing a priori risk and
to determine the screening efficiency and likelihood ratios (LRs) for T21 in fetuses found to have
EIFs on sonography. This information would be
useful for adjusting a patient’s risk before invasive diagnostic testing.

Materials and Methods
This was a retrospective cohort study of pregnancies presenting to our prenatal ultrasound units
over 16 years (1990–2006). Approval from the
Institutional Review Board at our center was
obtained. All fetal anomalies were coded since
the beginning of the study time frame in our prenatal database. A computerized database search
was performed to identify patients with EIFs and
stratified on the basis of a priori risk factors.
Gestational ages were confirmed by either firstor second-trimester sonography.
An EIF was defined as a fetal intracardiac lesion
that appeared as bright as bone and was detected in at least 2 of 4 standard views during a cardiac examination. The standard views include
the apical (4-chamber), lateral (septal), left ventricular outflow tract, and cardiac short axis. In
cases in which a karyotype was obtained, the
1640

diagnosis of an EIF was made sonographically
before knowledge of the karyotype. Fetal karyotypes were confirmed either by prenatal chromosomal analysis or postnatal examination.
When postnatal examination findings were suspicious for a chromosomal abnormality, the
karyotype was confirmed by a formal postnatal
study. Dedicated outcome coordinators routinely obtain outcome information on patients seen
in our center.
The sensitivity, specificity, positive predictive
value (PPV), and negative predictive value (NPV)
were calculated for the presence of an EIF and T21.
Positive and negative LRs were then determined,
and the 95% confidence intervals (CIs) around
these estimates were calculated. Contingency
table analysis of the presence of an EIF and diagnosis of fetal T21 for screening efficiency parameters was performed. The groups analyzed
included the following: (1) all fetuses with EIF
plus other sonographic markers, (2) a group the
same as group 1 except that the EIF was an isolated sonographic marker, (3) those younger
than 35 years with an isolated finding of an EIF
independent of serum screening; and (4) a group
with an isolated finding of an EIF excluding those
at increased risk for T21 on serum screening. The
statistical significance for the association of an
EIF and T21 was determined by calculating the
P values. P < .05 was considered statistically significant. All statistical analyses were performed
with Stata version 9.0 software (StataCorp,
College Station, TX).

Results
In the cohort of 62,111 pregnancies referred for
sonography and genetic evaluation, EIFs were
diagnosed in 2223 fetuses (3.6%). Trisomy 21 was
diagnosed in 218 of the overall cohort (0.4%).
Characteristics of the study cohort and indications for sonography are shown in Table 1. Thirtyfour of the 218 T21 cases had an EIF, and it was an
isolated finding in 14 cases. A list of associated
sonographic findings in the nonisolated EIFs is
presented in Table 2.
Analyzing women younger than 35 years
allowed evaluation of 42,964 pregnancies. In this
cohort, there were 80 cases of T21 (0.1%). Five of
the 80 cases (6.3%) had an isolated EIF. There
J Ultrasound Med 2009; 28:1639–1643
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were 1536 pregnancies with an isolated EIF in
the 42,884 pregnancies without T21 (3.6%).
In the cohort of patients without evidence of an
increased risk for aneuploidy on serum screening, there were 57,373 pregnancies available for
analysis. In this group, there were 155 cases of
T21 (0.3%), and 8 of 155 (5.2%) had an EIF, compared with the 1848 fetuses with an isolated EIF
in the 57,218 pregnancies without T21 (3.2%).
Efficiency parameters of an EIF in patients with
differing a priori risk for the diagnosis of T21
were obtained. The sensitivity, specificity, PPV,
NPV, and positive and negative LRs were calculated and are displayed in Table 3. For patients
with an EIF (including any other sonographically detected anomalies), the positive LR was
4.4 (95% CI, 3.2–6.0). When an EIF was an isolated finding, the positive LR was 2.0 (95% CI,
1.2–3.3). For patients younger than 35 years with
an isolated EIF, the positive LR was 1.7 (95% CI,
0.7–4.1). For patients with low-risk serum screening for aneuploidy, the positive LR was 1.60 (95%
CI, 0.8–3.1).
For the entire cohort, there were 2368 patients
with major anomalies, constituting 3.81% of
the study population. These major anomalies
included central nervous system defects, congenital heart disease, a diaphragmatic hernia,
omphalocele, gastroschisis, a cleft lip, a clubfoot,
and renal disorders. Among the patients older
than 35 years, 493 had a major anomaly (2.6%).
In the patients with abnormal serum screening
results, there were 148 patients with a major
anomaly (3.1%).

Discussion
Our study provides definitive risk estimates for
patients with the finding of an EIF on sonographic scans of the fetus. For all fetuses with an
EIF, including those with other sonographic
markers and risk factors, the risk of T21 was
increased, with a positive LR of 4.4. In the entire
cohort when an EIF was an isolated finding, the
LR was less pronounced (2.0). Importantly, however, the presence of an isolated EIF in patients
younger than 35 years and those without an
increased risk for aneuploidy on serum screening did not have an increased risk for T21.
Although the positive LRs for these groups were
J Ultrasound Med 2009; 28:1639–1643

Table 1. Characteristics of the Study Group
Characteristic

n

Mean maternal age ± SD, y
30 ± 6.5
Mean gestational age at time of sonography ±
19.4 ± 1.9
SD, wk
Maternal race
White
41,987
Black
14,301
Asian
1,678
Hispanic
744
Other
3,401
Indication for sonography
Advanced maternal age
18,772
Routine anatomic survey
21,989
Abnormal serum screening results for aneuploidy
4,738
Abnormal serum screening results for neural tube
1,938
defects
Suspected anomaly
3,007
Previous child with aneuploidy
603
Family history of birth defects
3,888
Drug/teratogen exposure
1,258
Other
5,918

%

67.6
23.0
2.7
1.2

30.2
35.4
7.6
3.1
4.8
1.0
6.3
2.0
9.5

1.7 and 1.6, respectively, both had CIs that
crossed 1, and the results for these “low-risk”
groups were not statistically significant at the 5%
probability level.9
Maternal race did not significantly affect the
results of our study. There were 2107 EIFs found
in the 60,433 non-Asian patients (3.4%). In contrast, there were 1678 Asian patients in the study
cohort, and 116 had an EIF (6.9%). There were 6
cases of T21 in the Asian population, and only 1
of these had an EIF. Therefore, despite the knowledge of an association between EIFs and Asian
race,10 there were not enough T21 cases to comment on the risk of T21 in the Asian population
with EIFs.
The detection of an EIF is based on multiple
factors.11 The experience of the sonographer and
the thoroughness of the examination are vital for
Table 2. Association of Other Fetal Sonographic
Abnormalities in T21 Cases With an EIF
Sonographic Finding

Thickened nuchal fold
Cystic hygroma
Any major CNS anomaly
Congenital heart disease
Hyperechoic bowel
Renal pyelectasis

n

%

20
4
27
16
19
77

6.56
3.31
5.38
3.88
6.53
6.17

CNS indicates central nervous system.
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Table 3. Screening Efficiency of an EIF and T21

EIF Type

Patients
Cases of T21
With
in Patients
Sonographic
With This
Finding, n
Finding, n Sensitivity, %

EIF (all)

2223

34

EIF (isolated)

1998

14

iEIF (<age 35 y)

1541

5

iEIF (–IRSS)

1856

8

15.6
(11.1–21.1)
6.4
(3.6–10.5)
6.3
(2.1–14.0)
5.2
(2.2–9.9)

Specificity, %

PPV, %

NPV, %

LR+

96.4
(96.3–96.6)
96.8
(96.6–96.9)
96.4
(96.2–96.6)
96.8
(96.6–96.9)

1.5
(1.1–2.1)
0.7
(0.4–1.2)
0.3
(0.1–0.8)
0.4
(0.2–0.8)

99.7
(99.6–99.7)
99.7
(99.6–99.7)
99.8
(99.8–99.9)
99.7
(99.7–99.8)

4.4
(3.2–6.0)
2.0
(1.2–3.3)
1.7
(0.74–4.08)
1.6
(0.81–3.14)

LR–

P (χ2)

0.88
<.0001
(0.79–0.94)
0.97
.007
(0.91–0.99)
0.97
.20
(0.91–0.99)
0.98
.17
(0.93–1.00)

Values in parentheses are 95% CIs. EIF (all) includes fetuses with other markers of T21; EIF (isolated), only marker of T21; iEIF, isolated EIF; and
iEIF (–IRSS), isolated EIF with the increased risk on serum screening (IRSS) group removed.

accurate diagnoses. Also, as ultrasound equipment and technology improve, there may be an
increase in the rate of EIF detection. A common
indication for further imaging and diagnostic
testing, an EIF also has the potential to generate
considerable anxiety in parents. Therefore, it is
essential to accurately counsel patients on the
basis of the best available evidence.
The LR is useful in calculating posttest probabilities for patients undergoing a sonographic
examination. By taking a person’s pretest odds
(eg, risk for T21) and multiplying them by the
positive LR, we can derive a patient’s posttest
odds for the disease in question.9 The results of
our study show that for patients younger than 35
years and those with normal serum screening
results for aneuploidy, the finding of an isolated
EIF does not significantly adjust their risk for T21
before the sonographic findings.
The definitive prenatal diagnosis of fetal chromosomal abnormalities is accomplished only
through invasive diagnostic testing, and these
techniques should be available to all women
regardless of maternal age.12 However, both
amniocentesis and chorionic villus sampling are
associated with small but real risks of fetal loss
and other complications.13 Screening strategies
that use second-trimester sonographic findings
can help with this counseling process.
Strengths of our study included the large sample size and the use of a single institution. The
use of a single center allowed standardization of
the definition of an EIF and ensured that karyotype testing could be offered to all patients with
an increased risk for T21. Further strengthening
1642

our results was the finding of cases of T21 in our
low-risk population, which allowed us to more
accurately compute contingency table analyses.
Our study was not without its limitations. It was
a retrospective design, and additionally, there
was a possibility that some cases of EIFs were not
coded. Given that fetuses with normal karyotypes constituted 99.6% of our overall cohort, a
noncoded EIF would likely be a false-positive
result and thus would have potentially increased
both our PPV and specificity.
In addition, there was potential overlap in the
study populations of the patients younger than
35 years and those without evidence of abnormal
serum screening results for aneuploidy. However,
sonographic markers should be used to modify a
patient’s a priori risk for aneuploidy. Regardless
of age, if a patient has a low risk of T21 based on
serum screening, it can be conferred that the
presence of an isolated EIF does not substantially modify this risk. Conversely, patients younger
than 35 years who have an increased risk of T21
based on serum screening and an isolated EIF
should use the serum screening results for their
a priori risk. Future studies could address the
potential for overlap in the study populations.
The rate of major anomalies also differed
between the groups analyzed. Although biologically there should have been no difference
between the groups being evaluated, that the
women older than 35 years and those with
abnormal serum screening results had different
prevalence rates for major abnormalities may
have confounded the sensitivity for EIFs in these
groups.
J Ultrasound Med 2009; 28:1639–1643
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The discovery of an EIF should prompt a
detailed anatomic survey. However, the finding
of an isolated EIF on prenatal examination does
not appreciably increase the risk for fetal T21 in
populations not already at increased risk for this
disorder. An isolated EIF should be considered
an incidental finding in patients younger than
35 years and those without abnormal serum
screening results for aneuploidy. The risk to benefit ratio does not favor invasive genetic testing
in these subgroups.

12.

American College of Obstetricians and Gynecologists.
ACOG Practice Bulletin No. 88, December 2007: invasive
prenatal testing for aneuploidy. Obstet Gynecol 2007;
110:1459–1467.

13.

American College of Obstetricians and Gynecologists.
ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol 2007; 109:217–
227.
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